Core Viewpoint - Molina Healthcare, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims related to undisclosed adverse financial information during the specified class period from February 5, 2025, to July 23, 2025 [1][3]. Summary by Sections Class Action Details - The lawsuit is titled Hindlemann v. Molina Healthcare, Inc., and investors who acquired Molina securities during the class period have until December 2, 2025, to seek lead plaintiff status [1][2]. - The law firm Robbins Geller Rudman & Dowd LLP is representing the plaintiffs in this case [7]. Allegations Against Molina Healthcare - The lawsuit alleges that Molina Healthcare failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on reduced utilization of various healthcare services, which was not communicated to investors [3]. Financial Performance and Impact - On July 7, 2025, Molina reported adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - Following this announcement, Molina's stock price declined significantly, reflecting investor concerns over the company's financial guidance being cut by 10.2% at the midpoint for fiscal year 2025 [4]. - On July 23, 2025, Molina further reduced its full-year earnings guidance, reporting a GAAP net income of $4.75 per diluted share for Q2 2025, an 8% decrease year-over-year, and attributing this to a challenging medical cost trend environment [5]. The stock price fell nearly 17% after this news [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Molina - The lawsuit alleges that Molina failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a substantial cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and prospects were materially misleading and lacked a reasonable basis [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, encouraging affected investors to contact them before the December 2, 2025 deadline for lead plaintiff applications in a federal securities class action [1][3]. Summary by Sections Allegations Against Molina - The complaint alleges that Molina and its executives made false or misleading statements and failed to disclose material adverse facts regarding the company's medical cost trend assumptions, leading to a dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on reduced utilization of behavioral health, pharmacy, and inpatient and outpatient services, which could lead to significant cuts in financial guidance for fiscal year 2025 [3]. Financial Performance and Guidance Cuts - On July 7, 2025, Molina announced second-quarter financial results, reporting adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. Further Financial Declines - On July 23, 2025, Molina further reduced its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year-over-year [5]. - The new guidance indicated adjusted earnings would be no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - Additionally, the company cut its full-year 2025 GAAP net income guidance by 27% to $912 million, attributing this to a challenging medical cost trend environment [6]. - Following this news, Molina's stock price plummeted by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [6].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors who purchased Molina securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Molina - The lawsuit alleges that Molina failed to disclose material adverse facts regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a substantial cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that positive statements made by Molina regarding its business and operations were materially misleading and lacked a reasonable basis [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in representing client interests [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by December 2, 2025, to serve as lead plaintiff [2] - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [3]

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 lead plaintiff deadline in a securities class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. Group 2: Legal Representation - Investors are advised to select qualified counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience and resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose several material adverse facts, including issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [5]. - It is claimed that Molina's financial guidance for fiscal year 2025 was likely to be cut due to these undisclosed issues, which rendered the company's positive statements misleading [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Molina's management failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina's management regarding the company's business and prospects were materially misleading [5].

Core Viewpoint - Molina Healthcare, Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to securities law violations [1] Group 1 - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [1] - The investigation was announced on July 7, 2025, prior to the market opening, indicating a significant development for Molina Healthcare [1]

NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the “Class Period”), of the important December 2, 2025 lead plaintiff deadline. SO WHAT: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 2, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Molina's management failed to disclose critical adverse information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, and as a result, the company's financial guidance for fiscal year 2025 was likely to be cut [5]. - The lawsuit asserts that the positive statements made by Molina's management about the company's business and prospects were materially misleading [5].